<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04066023</url>
  </required_header>
  <id_info>
    <org_study_id>CP-2019-001</org_study_id>
    <nct_id>NCT04066023</nct_id>
  </id_info>
  <brief_title>Double-Blind Comparison of the Efficacy and Safety of C213 to Placebo for the Acute Treatment of Cluster Headaches</brief_title>
  <official_title>Randomized, Double-Blind, Multi-Center, Parallel-Group Comparison of the Efficacy and Safety of the C213 (Zolmitriptan Microneedle System) to Placebo for the Acute Treatment of Cluster Headaches</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zosano Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zosano Pharma Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, placebo-controlled study. Subjects who meet the entry criteria will
      be randomized o receive one of three blinded treatments [C213 1.9 mg patch and placebo patch;
      C213 3.8 mg (1.9 mg x 2 patches), two placebo patches] on Day 1 and will have up to 48 weeks
      to confirm and treat a cluster headache. Subjects will self-administer the patches and
      respond to questions in the electronic diary (eDiary) until 1-hour post treatment
      administration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blinded, placebo-controlled study. Approximately 120 subjects
      who meet the entry criteria will be randomized 1:1:1 to receive one of three blinded
      treatments [C213 1.9 mg patch and placebo patch; C213 3.8 mg (1.9 mg x 2 patches), two
      placebo patches].

      Qualified subjects will randomize to the double-blind treatment period at Day 1 and will have
      up to 48 weeks to confirm and treat a cluster headache. Using the eDiary to confirm they are
      experiencing a cluster headache, subjects will self-administer the patches and continue to
      respond to questions in the eDiary until 1-hour post treatment administration.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 3, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Qualified subjects are assigned to received a single administration of one of three blinded treatment assignments (one of two dose levels or placebo)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>All subjects, care providers, investigator, and outcomes assessors are blinded to randomized treatment assignment. Study drugs are blinded and identical in appearance.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects who achieve pain relief</measure>
    <time_frame>15 minutes</time_frame>
    <description>Pain relief is defined by a decrease in pain from severe to mild or none without the use of acute rescue medication.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects who achieve sustained pain relief</measure>
    <time_frame>15 minutes to 60 minutes</time_frame>
    <description>Sustained pain relief requires a pain rating of mild or none at each timepoint from 15 minutes to 60 minutes without the use of acute rescue medication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects that achieve pain relief</measure>
    <time_frame>5, 10, and 20 minutes</time_frame>
    <description>Pain relief is defined by a decrease in pain from sever to mild or none without the use of acute rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects that achieve sustained pain relief</measure>
    <time_frame>5 minutes to 60 minutes and 10 minutes to 60 minutes</time_frame>
    <description>Sustained pain relief requires a pain rating of mild or none at each timepoint within the time frame without the use of acute rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects that achieve pain freedom</measure>
    <time_frame>10 minutes and 15 minutes</time_frame>
    <description>Pain freedom is defined by a decrease in pain from severe to none without the use of acute rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects that achieve sustained pain freedom</measure>
    <time_frame>10 to 60 minutes and 15 to 60 minutes</time_frame>
    <description>Sustained pain freedom requires a pain rating of none at each timepoint within the time frame without the use of acute rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects using rescue therapy</measure>
    <time_frame>within 20 minutes</time_frame>
    <description>Listed and summarized</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects able to perform their usual daily activities as assessed by the subject</measure>
    <time_frame>within 20 minutes</time_frame>
    <description>Listed and summarized</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events and serious adverse events</measure>
    <time_frame>1-8 days</time_frame>
    <description>Coded by MedDRA and summarized</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Cluster Headache</condition>
  <arm_group>
    <arm_group_label>C213 1.9 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>C213, 1.9 mg administered as one 1.9 mg patch and one placebo patch</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C213 3.8mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>C213 3.8 mg administered as two 1.9 mg patches</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo microneedle system administered as two placebo patches</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C213 Microneedle System</intervention_name>
    <description>The C213 System is a proprietary disposable patch and a reusable applicator. The zolmitriptan-coated titanium microneedle array (3 cm^2 array) is attached to a 5 cm^2 adhesive patch.</description>
    <arm_group_label>C213 1.9 mg</arm_group_label>
    <arm_group_label>C213 3.8mg</arm_group_label>
    <other_name>Zolmitriptan Microneedle System</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The C213 System is a proprietary disposable patch and a reusable applicator. The placebo patch is a single use, 3 cm^2 Placebo (intracutaneous microneedle) system that contains no active ingredients.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>ZP Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Able to provide written informed consent

          2. Women or men 18 to 65 years of age

          3. Greater than 1-year history of episodic or chronic cluster headache with onset prior
             to 50 years of age. Diagnosis must comply with ICHD-3 (International Headache Society
             (IHS) diagnostic criteria). Diagnostic criteria must include a history of at least 5
             attacks not attributed to any other disorder that include all of the following
             criteria:

               1. Severe or very severe unilateral orbital, supraorbital and/or temporal pain
                  lasting 45-180 minutes (average, when untreated)

               2. Either or both of the following:

                    1. At least one of the following symptoms or signs, ipsilateral to the pain:

                         1. Conjunctival injection and/or lacrimation

                         2. Nasal congestion and/or rhinorrhea

                         3. Eyelid edema

                         4. Forehead and facial sweating

                         5. Miosis and or/ptosis

                    2. A sense of restlessness or agitation

               3. Attacks have a frequency between one every other day and eight per day for more
                  than half of the time when the disorder is active.

               4. Not better accounted for by another International Classification of Headache
                  Disorders (ICHD) diagnosis

          4. Cluster history during the 12-month period prior to the screening visit must include:

               1. At least 1 cluster period

               2. Averaging 2-6 headaches per day

               3. Lasting at least 7 days

          5. Subject can distinguish cluster headaches from other headaches (i.e., migraine and
             tension-type headaches)

          6. Women of child-bearing potential must not be pregnant, must agree to avoid pregnancy
             during the trial, and must use one of the following or be surgically sterilized:
             intrauterine device, or a hormonal contraceptive

          7. Able to understand the operation of the electronic diary and able to apply the demo
             study drug patch correctly.

        Exclusion Criteria:

          1. Contraindications to triptans

          2. Use of any prohibited concomitant medications within 30 days of screening

          3. History of hemiplegic migraine or migraine with brainstem aura

          4. Participation in another investigational trial within 30 days or 5 half-lives of
             investigational product (whichever is longer).

          5. Previous M207/C213 exposure in a clinical trial

          6. Subject has other significant pain problems that might confound the study assessments
             in the opinion of the investigator

          7. Diagnosis of any malignant disease (other than adequately treated or excised
             non-metastatic basal cell carcinoma or squamous cell carcinoma of the skin) within the
             5 years prior to screening

          8. History of unstable psychiatric illness requiring medication or hospitalization in the
             12 months prior to study initiation

          9. Subjects who have a known allergy or sensitivity to zolmitriptan or its derivatives or
             formulations

         10. Subjects who have a known allergy or sensitivity to adhesions

         11. Subjects who have skin lesions or tattoos covering the entire potential area(s) of
             C213 application

         12. Woman who are pregnant, breast-feeding or plan a pregnancy during this study

         13. Clinically significant liver disease [Alanine Aminotransferase (ALT) &gt; 150 U/L;
             Aspartate Aminotransferase (AST) &gt; 130 U/L or bilirubin &gt; 2x ULN]

         14. Clinically significant kidney disease (eGFR &lt; 60 ml/min / 1.73 mÂ² or to creatinine &gt;
             1.5 x ULN)

         15. Subject has clinically significant ECG findings, defined by:

               1. ischemic changes (defined as &gt; 1mm of down-sloping ST segment depression in at
                  least two contiguous leads)

               2. Q-waves in at least two contiguous leads

               3. clinically significant intra-ventricular conduction abnormalities (left bundle
                  branch block or Wolf-Parkinson-White syndrome)

               4. clinically significant arrhythmias (e.g., current atrial fibrillation)

         16. History of coronary artery disease (CAD), coronary vasospasm (including Prinzmetal's
             angina), aortic aneurysm, peripheral vascular disease or other ischemic diseases
             (e.g., ischemic bowel syndrome or Raynaud's syndrome)

         17. Three or more of the following CAD risk factors:

               1. Current tobacco use

               2. Hypertension (systolic BP &gt; 140 or diastolic BP &gt; 90) or receiving
                  anti-hypertensive medication for treatment of hypertension

               3. Hyperlipidemia - LDL &gt; 159 mg/dL and/or HDL &lt; 40 mg/dL (or on prescribed
                  anti-cholesterol treatment)

               4. Family history of premature coronary artery disease (CAD) (&lt; 55 years of age in
                  male first-degree relatives or &lt; 65 years of age in female first degree
                  relatives)

               5. Diabetes mellitus

         18. History of cerebral vascular accident (CVA), transient ischemic attacks (TIA), or
             seizures

         19. History of concurrent illness that requires hospitalization within 30 days prior to
             study initiation

         20. Any other household member currently participating in a C213 study or relative of site
             staff member

         21. Any reason to believe that compliance with the study requirements and completion of
             evaluations required for this study will not be possible

         22. Any language barrier that, in the opinion of the Investigator, would preclude
             communication and compliance with the study requirements

         23. History or current abuse of or dependence on alcohol or drugs that would interfere
             with the results or adherence to study requirements

         24. Any positive drug screens for phencyclidine (PCP), 3,4-methylenedioxy-methamphetamine
             (MDMA) (ecstasy), cocaine, and/or meth/amphetamine(s)

         25. Current or planned use of hallucinogens (e.g. psilocybin) during the trial

         26. Any clinically relevant abnormal findings in the physical exam, vital signs or
             laboratory tests that, in the opinion of the Investigator, may put the subject at risk
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Don Kellerman, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Zosano Pharma Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Whitney Halladay</last_name>
    <phone>(510) 745-4011</phone>
    <email>whalladay@zosanopharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peter Schmidt, MD</last_name>
    <phone>(510) 745-1251</phone>
    <email>pschmidt@zosanopharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Keck Medicine of USC</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rama Koppula</last_name>
      <email>sahai@usc.edu</email>
    </contact>
    <investigator>
      <last_name>Soma Sahai-Srivastava, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Tran</last_name>
      <email>trans@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Nada Hindiyeh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>California Medical Clinic for Headache</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatyana Neyman</last_name>
      <email>tneyman@drkudrow.com</email>
    </contact>
    <investigator>
      <last_name>David Kudrow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KI Health Partners LLC DBA New England Institute for Clinical Research</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelo Termine</last_name>
      <email>angelo@neinh.com</email>
    </contact>
    <investigator>
      <last_name>Kathleen B Mullin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlanta Headache Specialists</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wes Williams</last_name>
      <email>wwilliams@pandaneuro.com</email>
    </contact>
    <investigator>
      <last_name>Frank Berenson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New England Regional Headache Center, Inc.</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Gubber-Markley</last_name>
      <email>gubberdm@nerhc.org</email>
    </contact>
    <investigator>
      <last_name>Herbert Markley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nevada Headache Institute</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier Aradanas</last_name>
      <email>xaradanas@nvhi.net</email>
    </contact>
    <investigator>
      <last_name>Abraham Nagy, MDs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faith Alexandre</last_name>
      <email>faith.p.alexandre@hitchcock.org</email>
    </contact>
    <investigator>
      <last_name>Barbara Nye, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dent Neuro Institute, Buffalo</name>
      <address>
        <city>Amherst</city>
        <state>New York</state>
        <zip>14226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mollie Bower</last_name>
      <email>mbower@dentinstitute.com</email>
    </contact>
    <investigator>
      <last_name>Shivang Joshi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jefferson Headache Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Hopkins</last_name>
      <email>mary.hopkins@jefferson.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ashley Liautaud</last_name>
      <email>ashley.liautaud@jefferson.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Stephanie Nahas-Geiger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center- Neurology Clinic</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Fehmel</last_name>
      <email>jennifer.fehmel@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Deborah Friedman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 19, 2019</study_first_submitted>
  <study_first_submitted_qc>August 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2019</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Episodic cluster headache</keyword>
  <keyword>Chronic cluster headache</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cluster Headache</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zolmitriptan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

